Ultragenyx Pharmaceutical (RARE) Competitors $39.19 -0.27 (-0.68%) Closing price 03:25 PM EasternExtended Trading$39.19 0.00 (0.00%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RARE vs. GMAB, RDY, ASND, VTRS, QGEN, MRNA, BPMC, BBIO, VRNA, and ROIVShould you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Ultragenyx Pharmaceutical vs. Its Competitors Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Roivant Sciences Ultragenyx Pharmaceutical (NASDAQ:RARE) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk. Is RARE or GMAB more profitable? Genmab A/S has a net margin of 35.11% compared to Ultragenyx Pharmaceutical's net margin of -93.04%. Genmab A/S's return on equity of 18.08% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-93.04% -186.49% -36.81% Genmab A/S 35.11%18.08%14.52% Which has stronger valuation & earnings, RARE or GMAB? Genmab A/S has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$560.23M6.61-$569.18M-$5.88-6.66Genmab A/S$3.12B4.19$1.14B$1.7611.60 Which has more volatility & risk, RARE or GMAB? Ultragenyx Pharmaceutical has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Do analysts recommend RARE or GMAB? Ultragenyx Pharmaceutical currently has a consensus target price of $87.00, indicating a potential upside of 122.00%. Genmab A/S has a consensus target price of $37.60, indicating a potential upside of 84.22%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Genmab A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93Genmab A/S 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.67 Do insiders & institutionals believe in RARE or GMAB? 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor RARE or GMAB? In the previous week, Ultragenyx Pharmaceutical had 6 more articles in the media than Genmab A/S. MarketBeat recorded 9 mentions for Ultragenyx Pharmaceutical and 3 mentions for Genmab A/S. Ultragenyx Pharmaceutical's average media sentiment score of 0.79 beat Genmab A/S's score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryGenmab A/S beats Ultragenyx Pharmaceutical on 9 of the 17 factors compared between the two stocks. Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RARE vs. The Competition Export to ExcelMetricUltragenyx PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.73B$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-6.6621.4227.3820.03Price / Sales6.61285.81422.31120.16Price / CashN/A41.9536.6357.47Price / Book14.207.518.085.67Net Income-$569.18M-$55.05M$3.16B$248.47M7 Day Performance5.58%3.16%2.12%2.90%1 Month Performance7.66%5.92%4.43%5.75%1 Year Performance-2.54%5.82%35.62%21.36% Ultragenyx Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAREUltragenyx Pharmaceutical4.1578 of 5 stars$39.19-0.7%$87.00+122.0%-3.7%$3.73B$560.23M-6.661,294News CoverageGMABGenmab A/S3.596 of 5 stars$20.68-2.3%$39.17+89.4%-17.9%$13.26B$3.12B11.752,682High Trading VolumeRDYDr. Reddy's Laboratories2.8525 of 5 stars$15.31+0.5%$16.95+10.7%-2.3%$12.78B$3.81B23.2027,811ASNDAscendis Pharma A/S3.5544 of 5 stars$175.78-0.6%$220.67+25.5%+27.0%$10.75B$393.54M-27.991,017Analyst ForecastVTRSViatris3.8137 of 5 stars$8.85-0.2%$10.40+17.5%-10.5%$10.39B$14.74B-2.7932,000QGENQiagen3.9211 of 5 stars$46.72-0.1%$47.74+2.2%+22.8%$10.39B$2.00B117.145,765Dividend AnnouncementMRNAModerna4.3859 of 5 stars$25.67-0.9%$46.61+81.6%-74.1%$9.93B$3.14B-2.945,800Options VolumeBPMCBlueprint Medicines1.7239 of 5 stars$128.40+0.2%$128.06-0.3%+16.2%$8.29B$508.82M-51.98640BBIOBridgeBio Pharma4.706 of 5 stars$42.18+1.1%$56.67+34.3%+71.9%$8.01B$127.42M-11.95400News CoverageAnalyst ForecastInsider TradeAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share2.6433 of 5 stars$97.05+2.9%$101.10+4.2%+482.7%$7.87B$118.54M-48.5330Positive NewsAnalyst ForecastROIVRoivant Sciences1.9559 of 5 stars$11.50+0.4%$17.50+52.2%+3.9%$7.82B$29.05M-46.00860 Related Companies and Tools Related Companies Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Qiagen Alternatives Moderna Alternatives Blueprint Medicines Alternatives BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Roivant Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RARE) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
